Investor Centre
Our pipeline and lead compound SFX-01 is derived from our proprietary Sulforadex® technology.
Corporate Presentation
Erasmus Medical Center begins glioblastoma studies
26 - October - 2023Evgen announces the formal start of their collaborative project in glioblastoma with Dr Marjolein Geurts, neuro‐oncologist at the Erasmus University Medical Center, supported with a grant awarded by the KWF Dutch Cancer Society
Investor Meet Presentation – Proposed Acquisition of Chronos Therapeutics Ltd, Placing and Accompanying Retail Offer
21 - March - 2024CEO Dr Huw Jones, CBO Dr Helen Kuhlman and new CFO Toni Haenninen discuss Evgen's proposed acquisition of Chronos Therapeutics Ltd.
Company | Analyst |
---|---|
Cavendish | Mark Brewer |
Major Shareholder
Current Shareholder | Number of shares | Percentage holding |
---|---|---|
J. R. Kight | 33,100,000 | 12.0% |
Octopus Investments | 21,875,000 | 8.0% |
SPARK Impact | 16,186,446 | 5.9% |
Seneca Investment Managers | 14,932,071 | 5.4% |
AXA Framlington | 13,399,724 | 4.87% |
Chelverton Asset Management | 12,500,000 | 4.5% |
RAB Capital | 8,750,000 | 3.2% |
Newlands Capital | 8,314,815 | 3.0% |
The number of ordinary shares in issue is 274,888,117 all of which are in public hands. The Company does not hold any shares in Treasury.